Type I interferon is known to drive anti-tumor effect directly or indirectly on tumor and surrounding immune cells, but also acts to counter the anti-tumor effect by inducing CD8+ T cell exhaustion and upregulating immune-suppressive genes on tumor cells (Fenton et al., 2021). Here, CD8A is linked to neoplasm.